TAVO412 a Two-stage, Open-label, Phase I Study in Patients with Advanced/metastatic Solid Tumors Who Have Received Standard of Care
Latest Information Update: 19 Jan 2025
Price :
$35 *
At a glance
- Drugs TAVO-412 (Primary)
- Indications Adenocarcinoma; Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Tavotek Biotherapeutics
- 14 Jan 2025 New trial record